“Pay-for-Delay”: The EC fines Teva and Cephalon for delaying the market entry of a generic version of modafinil


By:  and Emilija Berzanskaite 

In November 2020, the European Commission (EC) fined Teva and Cephalon 60.5 million euros for reaching an agreement to delay the market entry of the cheaper, generic version of a neurostimulant used to treat excessive daytime sleepiness. The summary of the EC Decision (case AT.39686 Cephalon) is available here. This is the fourth decision adopted by the EC in relation to pay-for-delay agreements (the other three cases are AT. 39612 Servier, AT. 39226 Lundbeck, AT. 39685 Fentanyl).

Continue reading at blog.cuatrecasas.com